NCT00576979View on ClinicalTrials.gov

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 4, 2008

Primary Completion Date

May 30, 2016

Study Completion Date

February 3, 2026

Conditions
Leukemia
Interventions
DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given IV

PROCEDURE

allogeneic bone marrow transplantation

Occurs approximately 48 hours after completion of cyclophosphamide

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Occurs approximately 48 hours after completion of cyclophosphamide

PROCEDURE

peripheral blood stem cell transplantation

Occurs approximately 48 hours after completion of cyclophosphamide

RADIATION

intensity-modulated radiation therapy

Undergo IMRT

RADIATION

tomotherapy

Undergo IMRT using helical tomotherapy

Trial Locations (1)

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00576979 - Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter